|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008059,
umls-concept:C0034541,
umls-concept:C0087111,
umls-concept:C0146224,
umls-concept:C0205219,
umls-concept:C0205282,
umls-concept:C0282460,
umls-concept:C0677865,
umls-concept:C1274040,
umls-concept:C1556003,
umls-concept:C1556084
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2005-12-14
|
|
pubmed:abstractText |
The current Phase II study was conducted to evaluate the survival and toxicity observed in children with newly diagnosed brainstem gliomas who were treated with the daily radiotherapy with topotecan used as a radiosensitizer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
pubmed-author:Bernier-ChastagnerValerieV,
pubmed-author:BracardSergeS,
pubmed-author:ChastagnerPascalP,
pubmed-author:DozFrancoisF,
pubmed-author:GentetJean ClaudeJC,
pubmed-author:GrillJacquesJ,
pubmed-author:KalifaCC,
pubmed-author:LaithierVV,
pubmed-author:LejarsOO,
pubmed-author:LuporsiEE,
pubmed-author:MargueritteGG,
pubmed-author:Marie-CardineAA,
pubmed-author:MechinaudFF,
pubmed-author:MillotFF
|
|
pubmed:copyrightInfo |
Copyright 2005 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
104
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2792-7
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16265674-Adolescent,
pubmed-meshheading:16265674-Age Factors,
pubmed-meshheading:16265674-Brain Stem Neoplasms,
pubmed-meshheading:16265674-Child,
pubmed-meshheading:16265674-Child, Preschool,
pubmed-meshheading:16265674-Disease-Free Survival,
pubmed-meshheading:16265674-Female,
pubmed-meshheading:16265674-Glioma,
pubmed-meshheading:16265674-Humans,
pubmed-meshheading:16265674-Magnetic Resonance Imaging,
pubmed-meshheading:16265674-Male,
pubmed-meshheading:16265674-Neoplasm Invasiveness,
pubmed-meshheading:16265674-Neoplasm Staging,
pubmed-meshheading:16265674-Prognosis,
pubmed-meshheading:16265674-Radiation-Sensitizing Agents,
pubmed-meshheading:16265674-Radiotherapy Dosage,
pubmed-meshheading:16265674-Risk Assessment,
pubmed-meshheading:16265674-Survival Analysis,
pubmed-meshheading:16265674-Time Factors,
pubmed-meshheading:16265674-Topotecan,
pubmed-meshheading:16265674-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology Phase II Study.
|
|
pubmed:affiliation |
Radiotherapy Service, Centre Alexis Vautrin, Vandoeuvre-les-Nancy, France.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Clinical Trial, Phase II
|
